102
Participants
Start Date
July 7, 2017
Primary Completion Date
June 6, 2019
Study Completion Date
June 6, 2019
Eslicarbazepine acetate
eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
Eslicarbazepine Acetate
eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
NYU Winthrop Hospital, Clinical Trials Center, Mineola
Alleghany General Hospital (Allegheny Neurological Association), Pittsburgh
Penn State Hershey Medical Center, Hershey
Drexel University, Philadelphia
Temple University Lewis Katz School of Medicine, Philadelphia
George Washington Medical Faculty Associates, Washington D.C.
Balijeet Shethi, MD, Waldorf
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Wake Forest Baptist Health Sciences, Department of Neurology, Winston-Salem
UNC Inverstigal Drug Services, Chapel Hill
The Neurological Institute, PA, Charlotte
Georgia Neurology and Sleep Medicine Associates, Suwanee
Tallahassee Neurological Clinic, Tallahassee
Neurology Associates PA, Maitland
Neurological Services of Orlando, PA, Orlando
Pedicatric Neurology, PA, Orlando
Vero Beach Neurology And Reasearch Institue/The MS Center of Vero Beach, Vero Beach
Infinity Clinical Research, LLC, Hollywood
The Neurology Research Group, LLC, Miami
Laszlo J. Mate, MD, PA, North Palm Beach
Boca Raton Regional Hospital, Marcus Neuroscience Institute, Boca Raton
University of South Florida, Tampa
Medsol Clinical Research Center, Port Charlotte
University of South Alabaa Neurology Department, Mobile
Vanderbilt Epilepsy Clinic, Nashville
Associates in Neurology, PSC, Lexington
University of Kentucky Hospital, Chandler Medical Center, Lexington
University of Cincinnati Medical Center, Cincinnati
Wayne State University/Detroit Medical Center, Detroit
SSM Health Dean Medical Group, Madison
Minnesota Epilepsy Group, PA, Saint Paul
Minneapolis Clinic of Neurology, Golden Valley
Northwestern Medical Group, Deparment of Neurology, Chicago
Rush University Medical Center, Chicago
University of Kansas Medical Center, Kansas City
Ochsner Clinic Foundation, New Orleans
Sooner Clinical Research, Oklahoma City
Aston Ambulatory Care Center, Dallas
University of Texas Health Science Center at San Antonio Medical Arts and Research Center, San Antonio
Austin Epilepsy Care Center, Austin
Blue Sky Neurology, a Division of Carepoint PC, Englewood
Conslutants in Epilepsy & Neurology, PLLC, Boise
Banner University Medical Center Phoenix=Neuroscience Institute, Phoenix
Rancho Research Institute, Inc., Downey
Altman Clinical and Translational Research Institute, La Jolla
University of California-Irvine, Orange
Neuro-Pain Medical Center, Fresno
Hawaii Pacific Neuroscience, Honolulu
Providence Medical Group-Medford Neurology, Medford
University of Connecticut School of Mwdicine -UCONN Health, Farmington
Dartmouth-Hitchcock Medical Center, Lebanon
JFK Neuroscience Institute, JFK Medical Center, Edison
Clinical Research Center of NJ (CRCNJ), Voorhees Township
Londo Health Sciences Centre, University Hospital, London
Clinique D'Épilepsie Neuro Rive-Sud, Greenfield Park
Sumitomo Pharma America, Inc.
INDUSTRY